181 related articles for article (PubMed ID: 3234616)
21. [Synthesis and antiulcer activity of N-2-(2-hydroxy-2-phenyl)ethyl-N"-(methanesulfonyl)guanidine analogue of ranitidine. Development of a new antiulcer agent T-593].
Shibata H; Kusayanagi Y; Arai H; Hashiba K; Yamamoto Y; Onoda M
Yakugaku Zasshi; 1998 Mar; 118(3):88-104. PubMed ID: 9549432
[TBL] [Abstract][Full Text] [Related]
22. Animal pharmacology of reversible antagonism of the gastric acid pump, compared to standard antisecretory principles.
Kromer W; Postius S; Riedel R
Pharmacology; 2000 May; 60(4):179-87. PubMed ID: 10828742
[TBL] [Abstract][Full Text] [Related]
23. [Do anticholinergic drugs still have significance in the therapy of ulcer?].
Stockbrügger R
Leber Magen Darm; 1986 Nov; 16(6):344-57, 377. PubMed ID: 3807633
[No Abstract] [Full Text] [Related]
24. A comparison of some of the pharmacological properties of etintidine, a new histamine H2-receptor antagonist, with those of cimetidine, ranitidine and tiotidine.
Cavanagh RL; Usakewicz JJ; Buyniski JP
J Pharmacol Exp Ther; 1983 Jan; 224(1):171-9. PubMed ID: 6129316
[TBL] [Abstract][Full Text] [Related]
25. Cimetidine and ranitidine protect against cold restraint-induced ulceration in rat by suppressing gastric acid secretion.
Garrick T; Goto Y; Buack S; Guth P
Dig Dis Sci; 1987 Nov; 32(11):1261-7. PubMed ID: 3665681
[TBL] [Abstract][Full Text] [Related]
26. Telenzepine is at least 25 times more potent than pirenzepine--a dose response and comparative secretory study in man.
Londong W; Londong V; Meierl A; Voderholzer U
Gut; 1987 Jul; 28(7):888-95. PubMed ID: 3653758
[TBL] [Abstract][Full Text] [Related]
27. Telenzepine inhibits electrically-stimulated, acetylcholine plus histamine-mediated acid secretion in the mouse isolated stomach by blockade of M1 muscarine receptors.
Kromer W; Baron E; Boer R; Eltze M
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jan; 343(1):7-13. PubMed ID: 2030745
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology of ORF 17578, a new histamine H2-receptor antagonist: comparison with cimetidine and ranitidine.
Katz LB; Scott CK; Shriver DA
J Pharmacol Exp Ther; 1986 May; 237(2):404-10. PubMed ID: 2871172
[TBL] [Abstract][Full Text] [Related]
29. Anti-ulcer and secretion-inhibitory properties of the tricyclic derivative doxepin in rats and dogs.
Leitold M; Fleissig W; Merk A
Arzneimittelforschung; 1984; 34(4):468-73. PubMed ID: 6547610
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological regulation of gastric acid secretion in the apical membrane of parietal cells; a new target for antisecretory drugs.
Okabe S; Shimosako K; Amagase K
J Physiol Pharmacol; 2001 Dec; 52(4 Pt 1):639-56. PubMed ID: 11787764
[TBL] [Abstract][Full Text] [Related]
31. Effects of N-(3-[3-(1-piperidinylmethyl)phenoxy]propyl)-acetoxyacetamide hydrochloride (TZU-0460), a histamine H2-receptor antagonist, on gastric acid secretion and ulcer formation.
Tarutani M; Sakuma H; Shiratsuchi K; Mieda M
Arzneimittelforschung; 1985; 35(5):844-8. PubMed ID: 2862875
[TBL] [Abstract][Full Text] [Related]
32. Molecular pharmacological approaches to effects of capsaicinoids and of classical antisecretory drugs on gastric basal acid secretion and on indomethacin-induced gastric mucosal damage in human healthy subjects (mini review).
Szabó IL; Czimmer J; Szolcsányi J; Mózsik G
Curr Pharm Des; 2013; 19(1):84-9. PubMed ID: 22946903
[TBL] [Abstract][Full Text] [Related]
33. Effects of successive doses of nizatidine, cimetidine and ranitidine on serum gastrin level and gastric acid secretion.
Yamaji Y; Omata T; Abe T; Yoshida A; Ueki S; Aita H; Morita H; Chaki K; Segawa Y; Kurimoto T
Arzneimittelforschung; 1991 Sep; 41(9):954-7. PubMed ID: 1796924
[TBL] [Abstract][Full Text] [Related]
34. Hexaprazol antagonism to gastric electrical potential fall by acetylsalicylic acid in rat.
Lumachi B; Scuri R
Drugs Exp Clin Res; 1985; 11(10):693-702. PubMed ID: 3836856
[TBL] [Abstract][Full Text] [Related]
35. Simple approach to assess potentiated drug combinations in clinical trials: studies with pirenzepine plus H2-receptor antagonists.
Pöch G; Londong W
Int J Clin Pharmacol Ther Toxicol; 1985 Jun; 23(6):283-7. PubMed ID: 2862111
[TBL] [Abstract][Full Text] [Related]
36. Effects of the new H2-receptor antagonist 3-amino-4-[4- [4- (1-piperidinomethyl)-2-pyridyloxy]-cis-2-butenylamino]-3-cyclobutene-1, 2- dione hydrochloride on gastric acid secretion and ulceration.
Muramatsu M; Isobe Y; Arai I; Hirose-Kijima H; Usuki-Ito C; Nagai H; Aihara H; Otomo S
Arzneimittelforschung; 1990 Jan; 40(1):49-54. PubMed ID: 1971169
[TBL] [Abstract][Full Text] [Related]
37. Antisecretory and antiulcer activities of a potent new histamine H2-receptor antagonist with an intermediate duration of action.
Borella L; Russell J; Rimele TJ; Grimes D; Failli A; Mir GN
Arzneimittelforschung; 1988 Mar; 38(3):366-72. PubMed ID: 2898247
[TBL] [Abstract][Full Text] [Related]
38. Comparative antiulcer and antisecretory effects of various calcium antagonists.
Hertz F; Cloarec A
Gen Pharmacol; 1989; 20(5):635-40. PubMed ID: 2606332
[TBL] [Abstract][Full Text] [Related]
39. Stimulation by McN-A-343 and blockade by telenzepine of acid secretion in the mouse isolated stomach at histamine-liberating cells.
Kromer W; Baron E; Beinborn M; Eltze M; Simon WA
Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):68-75. PubMed ID: 2477717
[TBL] [Abstract][Full Text] [Related]
40. Modern approach to the evaluation of combined effects of single-dose trials and clinical time-course studies, exemplified by combinations of pirenzepine and H2-receptor antagonists.
Pöch G; Londong W
Int J Clin Pharmacol Ther Toxicol; 1993 Oct; 31(10):483-8. PubMed ID: 8262686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
